Newsletter
Sign up for the Fund's newsletter and get the lastest news, calls and events
| Titel Sort descending | Periode | Program | |
|---|---|---|---|
| Genbrug af brusevand til toiletskyl | 2020 - 2020 | Innobooster
|
|
|
Genbrug af brusevand til toiletskyl
Period
2020 - 2020
Region
Region Midtjylland Program
Innobooster Area
Ikke defineret Investment
Percentage
33 Invested
86.167 Budget
261.113 Partners
GWS - GreyWaterSolution ApS People
GWS - Grey Water Solution ApS
Read more about the project
| |||
| Genbrugsfilter | 2020 - 2021 | Innobooster
|
|
|
Genbrugsfilter
Period
2020 - 2021
Region
Region Hovedstaden Program
Innobooster Area
Ikke defineret Investment
Percentage
31.13 Invested
462.418 Budget
1.5 mill. Partners
Guldager AS People
GULDAGER A/S
Read more about the project
| |||
| Genbrugsmursten | 2022 - 2022 | Innobooster
|
|
|
Genbrugsmursten
Period
2022 - 2022
Region
Region Hovedstaden Program
Innobooster Area
Ikke defineret Investment
Percentage
35 Invested
214.200 Budget
612.000 Partners
Industriservice People
INDUSTRISERVICE V/KLAUS SAABY HANSEN
Read more about the project
| |||
| Genbrugsplast Plade Produktions Udvikling | 2024 - 2025 | Innobooster
|
|
|
Genbrugsplast Plade Produktions Udvikling
Period
2024 - 2025
Region
Program
Innobooster Area
Ikke defineret Investment
Percentage
35 Invested
387.450 Budget
1.1 mill. Partners
Plastic Projects Aps People
Read more about the project
| |||
| Genbrugsplast Plader | 2022 - 2023 | Innofounder
|
|
|
Genbrugsplast Plader
Period
2022 - 2023
Region
Region Hovedstaden Program
Innofounder Area
Ikke defineret Investment
Percentage
100 Invested
760.000 Budget
760.000 Partners
Plastic Projects ApS People
Plastic Projects ApS
Read more about the project
| |||
| Gene editing approach to cure alpha 1-antitrypsin deficiency using Twelve Bio’s CRISPR technology | 2023 - 2024 | Innobooster
|
|
|
Gene editing approach to cure alpha 1-antitrypsin deficiency using Twelve Bio’s CRISPR technology
Period
2023 - 2024
Region
Program
Innobooster Area
Ikke defineret Investment
Percentage
35 Invested
5.0 mill. Budget
14.2 mill. Partners
Twelve Bio ApS People
Read more about the project
| |||
| Gene therapy for acute leukemia | 2021 - 2023 | Innoexplorer
|
|
|
Gene therapy for acute leukemia
Period
2021 - 2023
Region
Region Midtjylland Program
Innoexplorer Area
Ikke defineret Investment
Percentage
100 Invested
1.5 mill. Budget
1.5 mill. Partners
Aarhus Universitet, Incuba Science Park - Skejby People
Aarhus Universitet, Incuba Science Park - Skejby
Read more about the project
| |||
| Generating a metabolically mature human skeletal muscle in vitro model using 3D bioprinting, innervation and actuation | 2022 - 2025 | Industrial Researcher
|
|
|
Generating a metabolically mature human skeletal muscle in vitro model using 3D bioprinting, innervation and actuation
Period
2022 - 2025
Region
Region Hovedstaden Program
Erhvervsforsker Area
Ikke defineret Investment
Percentage
46.19 Invested
1.2 mill. Budget
2.7 mill. Partners
Technical University of Denmark, Novo Nordisk A/S - E1 People
Novo Nordisk A/S - E1
Read more about the project
| |||
| Generating best in class pan specific antibodies for MAPPS | 2023 - 2024 | Innobooster
|
|
|
Generating best in class pan specific antibodies for MAPPS
Period
2023 - 2024
Region
Program
Innobooster Area
Ikke defineret Investment
Percentage
12.29 Invested
184.388 Budget
1.5 mill. Partners
Immunitrack APS People
Read more about the project
| |||
| Generation of human induced pluripotent stem cell-based models of the BBB in health and disease | 2025 - 2027 | Industrial Researcher
|
|
|
Generation of human induced pluripotent stem cell-based models of the BBB in health and disease
Period
2025 - 2027
Region
Program
Erhvervsforsker Area
Ikke defineret Investment
Percentage
27.04 Invested
1.1 mill. Budget
4.0 mill. Formålet med det foreslåede projekt er at udvikle humane stamcelle-baserede in vitro modeller af den raske og Alzheimers ramte blod-hjerne barriere (BBB) til præklinisk screening af nye lægemidlers evne til at trænge over den raske og sygdomsramte BBB. Modellerne vil blive udførligt karakterisereret og cellernes proteom sammenlignes med proteomet af endothelceller isoleret fra Alzheimers ramte hjerner, hvilket muliggør identificeringen af nye transportproteiner udtrykt i BBB.
Partners
University of Copenhagen, BIONEER A/S People
Read more about the project
| |||
| Generation of novel diabetes therapeutics II: proceedings through development | 2022 - 2023 | Innobooster
|
|
|
Generation of novel diabetes therapeutics II: proceedings through development
Period
2022 - 2023
Region
Program
Innobooster Area
Ikke defineret Investment
Percentage
1.13 Invested
153.722 Budget
13.6 mill. Partners
Embark Biotech ApS People
Read more about the project
| |||
| Generativ AI til augmented reality platform | 2025 - 2025 | Innobooster
|
|
|
Generativ AI til augmented reality platform
Period
2025 - 2025
Region
Program
Innobooster Area
Ikke defineret Investment
Percentage
35 Invested
635.906 Budget
1.8 mill. Partners
Hololink ApS People
Hololink ApS
Read more about the project
| |||
| Generativ kunstig intelligens i computerspil | 2023 - 2024 | Innobooster
|
|
|
Generativ kunstig intelligens i computerspil
Period
2023 - 2024
Region
Program
Innobooster Area
Ikke defineret Investment
Percentage
35 Invested
1.4 mill. Budget
4.0 mill. Partners
Artificial Mind ApS People
Read more about the project
| |||
| Generative AI for software development | 2023 - 2024 | Innofounder
|
|
|
Generative AI for software development
Period
2023 - 2024
Region
Program
Innofounder Area
Ikke defineret Investment
Percentage
100 Invested
430.000 Budget
430.000 Vi udvikler et generativt AI-system, der kan skrive computerprogrammer automatisk – alene ud fra en beskrivelse af hvad de skal kunne. Systemer af denne slags spås at overtage store dele af den globale softwareudvikling inden for en kort årrække. Eksisterende systemer, fx ChatGPT, skriver programmer ved at identificere mønstre i store mængder menneskeskabt data, mens vores system programmerer på egen hånd baseret på indsigter det selv har opnået.
I forhold til eksisterende AI-metoder, adskiller heukno’s metodik sig på to væsentlige punkter:
1) Systemet er udelukkende baseret på selvlæring: der bruges ingen eksterne træningsdata.
2) Systemet er transparent og kan ”forklare” hvordan det kommer frem til en løsning.
Transparens og forklarlighed er afgørende for troværdigheden – og ultimativt anvendeligheden – af AI-systemer, men det er samtidig egenskaber som eksisterende AI-systemer mangler. Vores system kan ikke alene generere ægte nye løsninger på usete problemer, det kan også forklare hvordan disse løsninger fremkommer. Vi mener, at vores tilgang har potentialet til at definere retningen for fremtidens generative AI-systemer og placere Danmark i centrum for denne udvikling.
Partners
heukno ApS People
Read more about the project
| |||
| Generering af repræsentativ biobank bestående af klinisk relevante Pseudomonas aeruginosa (P.a) isolater fra cystisk fibrose patienter til udvikling af multi-komponent vaccine | 2019 - 2020 | Innobooster
|
|
|
Generering af repræsentativ biobank bestående af klinisk relevante Pseudomonas aeruginosa (P.a) isolater fra cystisk fibrose patienter til udvikling af multi-komponent vaccine
Period
2019 - 2020
Region
Region Hovedstaden Program
Innobooster Area
Biotek, Medico og Sundhed Investment
Percentage
33 Invested
299.268 Budget
906.875 Partners
Evaxion Biotech People
EVAXION BIOTECH A/S
Read more about the project
| |||